Health
Monoclonal antibodies against MERS coronavirus show promise in phase 1 trial – Medical Xpress
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
General20 hours agoVictorian school teacher charged with soliciting child abuse material
-
General11 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Noosa News15 hours agoPalestine protesters forced into last-minute reroute
-
Business15 hours agoUp 20% in 2 days, are Codan shares a buy, hold or sell?